Biotechnology Trade Secrets Law In Russia.

1. Introduction

Biotechnology Trade Secrets Law in Russia concerns the legal protection of confidential scientific, technical, commercial and industrial information used in biotechnology research, pharmaceutical development, genetic engineering, medical technologies, vaccine production and biological manufacturing.

Biotechnology companies often possess valuable information that is not publicly available, including:

Genetic engineering methods and gene-editing processes.

DNA sequencing techniques and proprietary genomic databases.

Pharmaceutical formulas and biological compositions.

Vaccine manufacturing processes.

Cell-culture and tissue-engineering techniques.

Synthetic biology research and laboratory protocols.

Bioreactor designs and fermentation processes.

Clinical research data and experimental results.

Proprietary methods for producing enzymes, proteins and antibodies.

Russian law protects qualifying confidential commercial information primarily through the concept of know-how (секрет производства) and the legal regime of commercial secrets (коммерческая тайна).

The central legal framework consists of:

Civil Code of the Russian Federation, Part IV, particularly Articles 1465–1472.

Federal Law No. 98-FZ of 29 July 2004, On Commercial Secrets.

Federal Law No. 149-FZ of 27 July 2006, On Information, Information Technologies and Information Protection.

Federal Law No. 152-FZ of 27 July 2006, On Personal Data.

Federal Law No. 61-FZ of 12 April 2010, On Circulation of Medicines.

Federal Law No. 323-FZ of 21 November 2011, On the Fundamentals of Health Protection of Citizens in the Russian Federation.

The purpose of these laws is to protect commercially valuable biotechnology information while balancing scientific research, public health, employee rights and legitimate regulatory disclosure.

2. Legal Meaning of Biotechnology Trade Secrets

Article 1465 of the Russian Civil Code defines a production secret, commonly called know-how, as information of a technical, technological, organisational or commercial nature that:

Has actual or potential commercial value because it is unknown to third parties.

Is not freely accessible to third parties on a lawful basis.

Is subject to reasonable measures taken by its holder to preserve confidentiality.

This definition is particularly important for biotechnology businesses.

For example, a Russian biotechnology company may develop a new method of manufacturing therapeutic proteins. If the method is commercially valuable, not publicly accessible and properly protected through confidentiality measures, it may qualify as legally protected know-how.

Important distinction: Not every confidential laboratory document automatically becomes a trade secret. The statutory requirements must be satisfied.

3. Federal Law No. 98-FZ of 2004 on Commercial Secrets

The principal legislation governing commercial secrecy in Russia is Federal Law No. 98-FZ of 29 July 2004.

It establishes the legal framework for creating, maintaining, transferring and protecting confidential commercial information.

Important provisions include:

ProvisionLegal significance
Article 3Defines commercial secrecy and related concepts
Article 4Establishes the holder's rights to classify information
Article 5Identifies information that cannot be classified as commercial secrets
Article 6Regulates access to commercial-secret information
Article 10Establishes confidentiality protection measures
Article 11Governs employee obligations
Article 13Provides protection of commercial-secret information during inspections and investigations
Article 14Establishes liability for violations

Article 10 is especially important for biotechnology companies.

It requires the holder to establish an appropriate confidentiality system, including:

Identifying and listing protected information.

Restricting access to confidential information.

Maintaining records of individuals who receive access.

Regulating confidentiality obligations in employment and commercial contracts.

Marking documents and other material containing commercial-secret information appropriately.

Companies may also implement passwords, encryption, laboratory-access restrictions, cybersecurity controls and secure research databases.

These measures help demonstrate that the company has taken reasonable steps to preserve confidentiality.

Consultant Plus+1

 

4. Biotechnology Information Protected as Trade Secrets

Russian law does not restrict know-how protection to conventional industrial manufacturing. Scientific and technological information can also qualify under Article 1465 of the Civil Code.

The following biotechnology information may qualify.

A. Genetic engineering techniques

A company developing a proprietary gene-editing process may protect its unpublished experimental procedures, technical parameters and manufacturing methods as know-how.

For example, confidential information concerning the optimisation of a gene-editing system may have commercial value because competitors cannot readily access or reproduce the process.

B. Pharmaceutical formulations

Confidential drug formulations, manufacturing sequences, stabilisation techniques and proprietary production parameters may qualify as trade secrets.

However, the company must distinguish confidential manufacturing know-how from information that must legally be disclosed in regulatory submissions or product documentation.

C. Vaccine manufacturing

A biotechnology enterprise may protect:

Antigen-production methods.

Fermentation parameters.

Purification processes.

Stabilisation techniques.

Quality-control procedures.

Manufacturing optimisation data.

The protection applies only where the statutory requirements are satisfied.

D. Tissue engineering and regenerative medicine

Confidential information concerning scaffold fabrication, cell-expansion procedures, tissue-culture conditions and proprietary biomaterial production may qualify.

E. Synthetic biology

Trade-secret protection may extend to proprietary biological circuits, organism-engineering methods, fermentation optimisation and confidential laboratory protocols.

Nevertheless, information already publicly disclosed in scientific publications or patents generally cannot remain confidential in the disclosed form.

5. Excluded Information: Article 5 of Law No. 98-FZ

A biotechnology company cannot classify every item of information as a commercial secret.

Article 5 identifies categories of information that cannot receive commercial-secret protection.

Examples include legally required information concerning:

Certain constituent documents and state-register entries.

Documents authorising entrepreneurial activities.

Certain information concerning state and municipal property.

Environmental and other information that legislation requires to be accessible.

Certain information concerning employees and employment conditions.

Information concerning violations of law and other matters specified by legislation.

This is particularly significant for pharmaceutical and biotechnology businesses.

A company cannot use commercial secrecy as a general justification for withholding information that must legally be disclosed to regulators, courts or the public.

The statutory exclusions must be examined alongside the applicable sector-specific legislation.

WIPO+1

 

6. Ownership of Biotechnology Trade Secrets

Articles 1466–1471 of the Russian Civil Code establish the rules governing ownership and commercial exploitation of know-how.

Article 1466: Exclusive right

The holder of a production secret enjoys an exclusive right to use the protected information through lawful commercial methods.

For example, a biotechnology company may control the commercial use of its confidential antibody-production process.

Importantly, Russian law recognises that another person who independently and in good faith obtains the same information may acquire an independent exclusive right.

This means trade-secret protection does not automatically prevent independent scientific discovery.

Article 1467: Duration of protection

The exclusive right continues for as long as the information remains confidential.

Unlike patent protection, know-how protection does not have a predetermined statutory term of 20 years.

However, once confidentiality is lost, the exclusive right terminates.

Article 1468: Transfer of ownership

The holder may transfer its exclusive right to another person through an appropriate agreement.

For example, a Russian biotechnology enterprise may transfer ownership of its proprietary vaccine-production technology to another pharmaceutical company.

The transferring holder must continue preserving confidentiality until the exclusive right terminates.

Article 1469: Licensing

A biotechnology company may license its know-how to another organisation.

The agreement should clearly specify:

The particular know-how being licensed.

The permitted technological applications.

Territorial restrictions, where agreed.

Duration and licensing fees.

Confidentiality obligations.

Restrictions on disclosure and sublicensing.

Security and reporting obligations.

Article 1470: Employee-created know-how

Where an employee develops a production secret in the performance of employment duties or a specific employer assignment, the exclusive right belongs to the employer.

The employee must preserve confidentiality for as long as the exclusive right remains effective.

Article 1471: Contractual research

This provision regulates ownership of know-how produced under research, development and technological contracts, including certain government contracts.

As a general rule, the contractor owns the resulting production secret, subject to statutory exceptions and applicable contractual provisions.

These provisions are particularly relevant to biotechnology research conducted jointly by universities, pharmaceutical companies, laboratories and government research institutions.

rospatent.gov.ru+1

 

7. Trade Secrets and Patent Protection in Biotechnology

One of the most important legal questions concerns whether biotechnology inventions should be protected through patents or trade secrets.

Legal issuePatent protectionTrade-secret protection
Main legislationCivil Code Part IVCivil Code Articles 1465–1472
Public disclosureRequired through patent publicationConfidentiality required
Protection periodGenerally 20 years for inventions, subject to applicable rulesWhile confidentiality continues
Independent discoveryPatent rights may prevent unauthorised use within their scopeIndependent lawful acquisition is permitted
RegistrationPatent application and grantNo patent registration required
Main commercial advantageExclusionary patent rightsProtection without public disclosure

Example:

A Russian biotechnology company develops a new therapeutic protein.

It may consider patenting a qualifying invention concerning the protein or its production process while preserving undisclosed manufacturing parameters as trade secrets.

However, the company must consider whether the patent application itself will disclose information that it wishes to keep confidential.

A particularly important distinction is that an invention disclosed in a patent cannot ordinarily be protected as a trade secret in respect of the information made public.

8. Protection Against Employee Misappropriation

Biotechnology companies frequently employ scientists, laboratory technicians, bioinformaticians, genetic engineers and pharmaceutical researchers.

Employees may gain access to valuable confidential information during their employment.

Article 1470 of the Civil Code provides that the employer owns the exclusive right to qualifying employee-created know-how.

Article 11 of Federal Law No. 98-FZ also establishes employee obligations concerning commercial-secret information.

Potential violations include:

Copying proprietary genomic databases.

Transferring laboratory protocols to competitors.

Disclosing confidential vaccine formulations.

Taking confidential pharmaceutical manufacturing documents.

Sharing unpublished experimental results without authorisation.

Using proprietary research information for unauthorised commercial purposes.

Employers should maintain written confidentiality policies, access records, employee agreements and exit procedures.

However, confidentiality agreements cannot lawfully eliminate employees' rights to engage in independent professional activities or restrict access to information that cannot legally be classified as confidential.

9. Biotechnology Research Contracts and Trade-Secret Licensing

Research collaboration creates particular difficulties because biotechnology projects frequently involve multiple institutions.

For example, a pharmaceutical company may collaborate with:

A Russian public university.

A private biotechnology laboratory.

A foreign pharmaceutical manufacturer.

A clinical research organisation.

A medical-device developer.

Each party may contribute different technical information and intellectual property.

Contracts should distinguish between:

Background know-how: Confidential information owned by a party before the collaboration.

Foreground know-how: New confidential information generated during the research project.

Jointly developed information: Information created through the contributions of multiple parties.

A well-drafted agreement should specify ownership, permitted use, confidentiality, publication approval, access to laboratory records, sublicensing and post-termination obligations.

Under Article 1471, ownership of know-how produced through contractual research must be considered in accordance with the statutory allocation rules and applicable contractual arrangements.

This is particularly important where a publicly funded institution contributes to a commercially valuable biotechnology discovery.

10. Important Russian Case Laws on Trade Secrets and Know-How

Russian courts have developed important principles concerning the identification, ownership, transfer and unauthorised disclosure of confidential technical information.

There is an important research qualification: the following are general Russian know-how and commercial-secret precedents relevant to biotechnology. They should not be represented as cases specifically involving biotechnology unless the underlying judgment establishes that connection.

Case 1. Supreme Court of the Russian Federation – 25 July 2025

Case No. А65-31236/2023, Determination No. 306-ЭС25-461

Supreme Court authority

Facts:

The dispute concerned a licensing agreement for the transfer of know-how.

The licensee argued that it had paid part of the agreed fee but had not received the production secret promised under the agreement.

The lower courts had treated the agreement as concluded and considered that the know-how had been transferred.

Legal issue:

Whether the agreement sufficiently identified the particular know-how and whether the promised confidential information had actually been transferred.

Decision:

The Supreme Court set aside the lower courts' decisions and remanded the matter for reconsideration.

It emphasised the need to investigate:

What particular information constituted the subject matter of the agreement.

Whether the parties had agreed on a specific production secret.

Whether the information had actually been transferred.

Whether the agreement concerned know-how or another type of contractual service.

Legal principle:

A general reference to know-how is not necessarily sufficient. Courts must examine the actual confidential information covered by the contract and the evidence of its transfer.

Biotechnology significance:

Suppose a Russian biotechnology company licenses a proprietary tissue-engineering process to a foreign manufacturer. Merely providing access to an online training platform may not establish that all the specifically contracted technical information has been transferred.

The parties should document the actual protocols, technical specifications and confidential materials delivered.

Source:

Документы ленты ПРАЙМ: ГАРАНТ.РУ+1

 

Case 2. Eleventh Arbitration Court of Appeal – 17 September 2019

Case No. А40-274664/2018

Parties: JSC Research Institute of Steel and the Federal Service for Intellectual Property (Rospatent).

Facts:

The dispute concerned the recognition of authorship and remuneration relating to intellectual-property results created by employees.

The issue included whether employees who contributed creatively to the creation of know-how could have legally recognised authorship and associated remuneration rights.

Legal issue:

Whether the fact that an employer owns the exclusive right to employee-created know-how prevents recognition of the individual employees who created it.

Decision:

The appellate court rejected the relevant challenge and recognised the significance of employee creative contribution.

It explained that the statutory ownership of the exclusive right by an employer under Article 1470 does not eliminate the question of authorship.

Legal principle:

Ownership of the exclusive commercial right and authorship are distinct legal questions.

Biotechnology significance:

Where scientists collectively develop a proprietary cell-culture technique, the employer may own the exclusive right to the qualifying know-how, while the individual researchers' contributions remain relevant to authorship and any applicable remuneration arrangements.

Source:

ГАРАНТ

 

Case 3. Presidium of the Supreme Arbitration Court – Plenary Resolution No. 5/29, 26 March 2009

Paragraph 57 – Protection of Production Secrets (Know-How)

Legal issue:

The interpretation of legal protection for production secrets under Russian intellectual-property law.

Legal principle:

The resolution explains that courts must consider the requirements of Article 1465 of the Civil Code and the confidentiality regime established under Federal Law No. 98-FZ.

It also clarifies that liability under Article 1472 may extend to persons who disclose protected know-how, including public-law entities where the relevant legal requirements are satisfied.

Biotechnology significance:

A government laboratory, regulatory authority or research institution that receives confidential biotechnology information cannot assume that public-sector status automatically removes its confidentiality obligations.

For example, confidential vaccine-manufacturing information received during an official inspection may remain protected against unauthorised disclosure.

Source:

Верховный Суд Российской Федерации

 

Case 4. Supreme Court – General Principle of Independent Know-How Acquisition

Civil Code Article 1466(2), applied to know-how disputes

This is a statutory legal principle rather than a separate case judgment.

Article 1466(2) recognises that a person who independently and in good faith obtains information constituting know-how may acquire an independent exclusive right.

Biotechnology significance:

Two biotechnology laboratories may independently develop similar techniques for producing a therapeutic protein.

The first laboratory cannot automatically claim infringement merely because the second laboratory's process resembles its own.

The decisive questions include whether the second laboratory independently developed the information or unlawfully obtained the first laboratory's confidential materials.

Source:

rospatent.gov.ru+1

 

11. Civil Liability for Biotechnology Trade-Secret Violations

Article 1472 of the Civil Code establishes liability for infringement of the exclusive right to a production secret.

A person who unlawfully obtains and discloses or uses protected know-how may be required to compensate the damage caused.

Liability can also apply to persons who were legally or contractually required to preserve confidentiality.

Examples include:

A former researcher disclosing a proprietary genetic-engineering method.

A contractor transferring confidential pharmaceutical production data.

A laboratory employee selling proprietary biological research results.

A licensee using confidential manufacturing technology beyond the agreed contractual scope.

The claimant must establish the relevant legal requirements, including the existence of protected know-how, its entitlement to protection, the defendant's unlawful conduct and the legally recoverable damage.

Possible remedies include:

Compensation for proven losses.

Recovery of damages arising from contractual breaches.

Injunctive or other appropriate protective relief where legally available.

Contractual remedies for unauthorised disclosure or misuse.

Protection against continuing unlawful exploitation.

An important issue is that a company cannot simply claim ownership over information without establishing that the information meets the statutory definition of know-how.

Source:

rospatent.gov.ru+1

 

12. Criminal Liability for Trade-Secret Theft

Russian criminal law also provides protection against unlawful acquisition and disclosure of commercial secrets.

Article 183 of the Criminal Code of the Russian Federation addresses unlawful acquisition and disclosure of information constituting commercial, tax or banking secrets.

Potential biotechnology-related offences may involve:

Unlawful acquisition of confidential pharmaceutical formulas.

Theft of proprietary genetic research.

Disclosure of confidential vaccine-production information.

Commercial exploitation of unlawfully obtained laboratory data.

Disclosure of protected research information by a person entrusted with it.

The precise criminal offence and applicable punishment depend on the conduct, the method of acquisition, the person's position, the relevant statutory elements and any aggravating circumstances.

Criminal proceedings are separate from civil claims for infringement of know-how rights.

13. Biotechnology Trade Secrets and Personal Genetic Data

A particularly complex issue arises when trade secrets contain human genetic or medical information.

For example, a biotechnology enterprise may possess:

DNA sequencing results.

Patient genomic profiles.

Clinical-trial datasets.

Genetic susceptibility information.

Personalised medicine research records.

These materials may involve overlapping legal protections.

Federal Law No. 152-FZ on Personal Data is relevant where information constitutes personal data.

Genetic information connected to an identifiable individual may qualify as personal data and, depending on its nature and context, may also fall within the statutory category of special categories of personal data concerning health.

This creates an important distinction:

The company's proprietary analytical method may qualify as know-how.

A patient's identifiable genetic information is subject to personal-data protection requirements.

A company's trade-secret classification does not eliminate the patient's legal rights.

Consequently, biotechnology companies must consider both intellectual-property protection and personal-data compliance.

14. Trade Secrets and Pharmaceutical Regulatory Disclosure

Biotechnology companies operating in Russia may need to provide confidential technical information to regulatory authorities.

For example, pharmaceutical manufacturers may submit information concerning:

Drug composition.

Manufacturing methods.

Product stability.

Clinical-trial results.

Quality-control systems.

Manufacturing facilities.

Federal Law No. 61-FZ on Circulation of Medicines is particularly relevant.

The company may seek protection for commercially sensitive information submitted to regulators, but it cannot refuse a legally required disclosure simply by labelling the information a trade secret.

A distinction must be maintained between:

Confidential commercial information.

Legally mandatory regulatory disclosures.

Information subject to statutory access restrictions.

Information that may be disclosed under a lawful regulatory or judicial procedure.

This distinction is essential for pharmaceutical manufacturers, vaccine producers and clinical research organisations.

15. Cross-Border Biotechnology Trade-Secret Protection

Russian biotechnology companies increasingly cooperate with foreign research institutions, pharmaceutical manufacturers and medical-technology businesses.

Cross-border collaboration creates additional legal risks.

Common disputes include:

Transfer of confidential genetic-engineering methods to foreign companies.

Unauthorised disclosure of pharmaceutical formulas.

Misuse of vaccine-manufacturing technology.

International employee mobility and confidentiality disputes.

Transfer of confidential laboratory databases.

Disputes concerning ownership of jointly developed biotechnology.

Unauthorised use of research information by foreign licensees.

Russian companies should address these issues through detailed international licensing and research agreements.

Contracts should specify the governing law, dispute-resolution forum, ownership of research results, confidentiality obligations, permitted disclosures and procedures for handling confidential information after termination.

Foreign companies must also consider applicable laws in the countries where research, manufacturing and data processing occur.

16. Practical Compliance Framework for Russian Biotechnology Companies

A biotechnology enterprise should implement an organised system for protecting its confidential research and commercial information.

Recommended compliance framework

Identify confidential information

Prepare an inventory of proprietary laboratory protocols, research results, formulas, databases and production processes.

Establish commercial-secret status

Adopt an internal commercial-secret policy under Federal Law No. 98-FZ.

Control laboratory access

Restrict physical and digital access to sensitive research facilities and databases.

Protect employee information

Introduce appropriate confidentiality obligations and employee access controls.

Regulate research partnerships

Establish clear ownership and confidentiality provisions in research and development agreements.

Secure digital research records

Use encryption, access logs, authentication and controlled data-sharing systems.

Prepare for legal enforcement

Maintain evidence of ownership, confidentiality measures, access history and unauthorised disclosures.

17. Major Legal Challenges

Russian biotechnology trade-secret protection faces several important challenges.

Legal challengeSignificance
Genetic research confidentialityProtecting commercially valuable research without violating individual rights
Employee mobilityPreventing unauthorised disclosure while respecting employee rights
University collaborationDetermining ownership of jointly developed research
AI-generated biotechnologyIdentifying ownership and confidentiality of computational research outputs
CybersecurityPreventing theft of digital laboratory information
Patent conflictsDeciding which information should be patented and which should remain confidential
Regulatory disclosureBalancing confidentiality with mandatory government disclosure
International licensingEnforcing contractual confidentiality across jurisdictions

18. Suggestions for Legal and Regulatory Reform

Several developments could strengthen biotechnology trade-secret protection in Russia:

More detailed guidance on protecting genomic research databases.

Standardised contractual provisions for university–industry biotechnology collaborations.

Improved legal procedures for identifying and proving digital trade-secret theft.

Clearer rules governing confidentiality in AI-assisted scientific research.

Better coordination between intellectual-property authorities and pharmaceutical regulators.

Stronger safeguards for confidential information transferred through international research partnerships.

Greater clarity concerning the relationship between employee-created know-how and remuneration rights.

These reforms could improve legal certainty for biotechnology investors, researchers and pharmaceutical manufacturers.

19. Conclusion

Biotechnology Trade Secrets Law in Russia is primarily governed by Articles 1465–1472 of the Civil Code and Federal Law No. 98-FZ of 2004.

The legal framework provides protection for commercially valuable scientific, technological, organisational and manufacturing information, provided that the statutory confidentiality requirements are satisfied.

Its importance extends across genetic engineering, synthetic biology, pharmaceutical manufacturing, vaccine production, tissue engineering, regenerative medicine and biotechnology research.

The Russian legal system recognises exclusive rights in qualifying know-how, regulates employee-created inventions and confidential information, permits licensing and contractual transfers, and provides civil and criminal remedies against unlawful acquisition and disclosure.

The 2025 Supreme Court decision in Case No. А65-31236/2023 is particularly significant because it demonstrates the importance of identifying the specific know-how covered by a licensing agreement and proving its actual transfer.

Ultimately, effective biotechnology trade-secret protection requires more than confidentiality agreements. It requires a legally established secrecy regime, reliable technical safeguards, clear ownership arrangements and enforceable contractual obligations.

20. Important Legal References and Research Sources

Legal authorityRelevant provisions
Russian Civil Code, Part IVArticles 1465–1472
Federal Law No. 98-FZ (2004)Commercial secrets
Federal Law No. 149-FZ (2006)Information protection
Federal Law No. 152-FZ (2006)Personal data
Federal Law No. 61-FZ (2010)Circulation of medicines
Criminal CodeArticle 183
Resolution No. 5/29 (2009)Paragraph 57, know-how protection

Primary research materials:

Russian Civil Code – official Rospatent-hosted English text.

WIPO Lex – Federal Law No. 98-FZ on Trade Secrets.

Supreme Court determination, 25 July 2025 – Case No. А65-31236/2023.

Eleventh Arbitration Court of Appeal – Case No. А40-274664/2018.

Resolution No. 5/29 of 26 March 2009 – Paragraph 57.

Academic note: This is a research-oriented explanation, not an exhaustive database of Russian biotechnology litigation. The cited judicial decisions concern general know-how principles rather than specifically adjudicated biotechnology trade-secret disputes. The applicable statutory text and amendments should be checked before relying on this analysis in litigation or commercial transactions.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT